Ajani JA et al. Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2), HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. ESMO 2023;Abstract LBA82.
André T et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GRECOR NEONIPIGA phase II study. J Clin Oncol 2023;41(2):255-65. Abstract
Chuang J et al. Therapeutic advances and challenges in the management of HER2-positive gastroesophageal cancers. Diseases 2022;10(2):23. Abstract
Friedman CF et al. Atezolizumab treatment of tumors with high tumor mutation burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study. Cancer Discov 2022;12(3):654-69. Abstract
Fucà G et al. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer 2022;10(2):e004001. Abstract
Gandara DR et al. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. ASCO 2023;Abstract 2503.
Janjigian YY et al. Nivolumab (nivo) plus chemotherapy (chemo) vs chemotherapy as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649. Gastrointestinal Cancers Symposium 2023;Abstract 291.
Janjigian YY et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023;[Online ahead of print]. Abstract
Janjigian YY et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. Gastrointestinal Cancers Symposium 2022;Abstract 295.
Kasi PM et al. Pan-cancer prevalence of microsatellite instability-high (MSI-H) identified by circulating tumor DNA and associated real-world clinical outcomes. JCO Precis Oncol 2023;7:e2300118. Abstract
Kato K et al. Nivolumb (nivo) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. Gastrointestinal Cancers Symposium 2023;Abstract 290.
Kelly RJ et al. Adjuvant nivolumab (nivo) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analysis of CheckMate 577. ASCO 2021;Abstract 4003.
Klempner SJ et al. ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Can Res 2023;29(19):3882-91. Abstract
Ku G et al. First-in-human phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody in advanced solid tumors. ESMO 2023;Abstract 1039P.
Ku G et al. Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. ESMO 2022;Abstract 1205MO.
Lee K-W et al. Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish). Gastrointestinal Cancers Symposium 2023;Abstract TPS484.
Lordick F et al. Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophgeal junction (mG/GEJ) adenocarcinoma. ESMO 2023;Abstract LBA81.
Maron SB, Klempner SJ. Are you a TMBeliever? Mutations and atezolizumab response in solid tumors. Cancer Discov 2022;12(3):602-3. Abstract
Randon G et al. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockades. J Immunother Cancer 2023;11(6):e007104. Abstract
Shen L et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study. J Clin Oncol 2022;40(26):3065-76. Abstract
Shitara K et al. Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas. ASCO 2023;Abstract TPS4173.
Staller KD et al. Case 31-2022: A 72-year-old man with heartburn, nausea, and inability to eat. N Engl J Med 2022;387(15):1415-24. Abstract
Tabernero J et al. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol 2022;18(29):3255-66. Abstract
Van Cutsem E et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol 2023;24:744-56. Abstract
Vora KB et al. Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers. Gastrointestinal Cancers Symposium 2023;Abstract 43.
Xu J et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023;24(5):483-95. Abstract
Xu R-H et al. Tislelizumab (tis) plus chemotherapy (chemo) versus placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. ESMO 2023;Abstract LBA80.
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.